Novel vaccination approaches against equine alphavirus encephalitides

Autores
Carossino, Mariano; Thiry, Etienne; Grandière, Ana de la; Barrandeguy, Maria Edith
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The current production of inactivated vaccines for the prevention of equine alphavirus encephalitides caused by Eastern, Western and Venezuelan Equine Encephalitis viruses (EEEV, WEEV, VEEV) involves the manipulation of large quantities of infectious viral particles under biosafety level 3 containment laboratories with the potential risk of transmission to the operators. Moreover, these vaccines are not capable of inducing a long-lasting immunity. Modified live vaccines, which were also attempted, maintain residual virulence and neurotropism, causing disease in both horses and humans. Therefore, the production of an efficacious second generation vaccine which could be used in the prevention of alphavirus infection without the need to manipulate infectious viral particles under high biocontainment conditions could be of great benefit for the worldwide horse industry. Furthermore, equine alphaviruses are considered as biological threat agents. Subunit, chimeric, gene-deleted live mutants, DNA and adenovirus-vectored alphavirus vaccines have been evaluated; such approaches are reviewed in this work. Climate changes, together with modifications in bird and vector ecology, are leading to the arise of emerging pathogens in new geographical locations, and these zoonotic New World arboviruses are gaining concern. Novel vaccine development does show a promising future for prevention of these infections in both horses and humans.
Instituto de Virología
Fil: Carossino, Mariano. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virologia; Argentina. Universidad del Salvador. Escuela de Veterinaria; Argentina
Fil: Thiry, Etienne. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; Bélgica
Fil: Grandière, Ana de la. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; Bélgica
Fil: Barrandeguy, Maria Edith. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Universidad del Salvador. Escuela de Veterinaria; Argentina
Fuente
Vaccine 32 (3) : 311-319 (January 2014)
Materia
Caballos
Enfermedades de los Animales
Alphavirus
Virus de la Encéfalo Mielitis Equina
Vacunación
Horses
Animal Diseases
Equine Encephalomyelitis Virus
Vaccination
Nivel de accesibilidad
acceso restringido
Condiciones de uso
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/4336
Acceder
id INTADig_97721af25c70c00e8017837b9a95175c
oai_identifier_str oai:localhost:20.500.12123/4336
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Novel vaccination approaches against equine alphavirus encephalitidesCarossino, MarianoThiry, EtienneGrandière, Ana de laBarrandeguy, Maria EdithCaballosEnfermedades de los AnimalesAlphavirusVirus de la Encéfalo Mielitis EquinaVacunaciónHorsesAnimal DiseasesEquine Encephalomyelitis VirusVaccinationThe current production of inactivated vaccines for the prevention of equine alphavirus encephalitides caused by Eastern, Western and Venezuelan Equine Encephalitis viruses (EEEV, WEEV, VEEV) involves the manipulation of large quantities of infectious viral particles under biosafety level 3 containment laboratories with the potential risk of transmission to the operators. Moreover, these vaccines are not capable of inducing a long-lasting immunity. Modified live vaccines, which were also attempted, maintain residual virulence and neurotropism, causing disease in both horses and humans. Therefore, the production of an efficacious second generation vaccine which could be used in the prevention of alphavirus infection without the need to manipulate infectious viral particles under high biocontainment conditions could be of great benefit for the worldwide horse industry. Furthermore, equine alphaviruses are considered as biological threat agents. Subunit, chimeric, gene-deleted live mutants, DNA and adenovirus-vectored alphavirus vaccines have been evaluated; such approaches are reviewed in this work. Climate changes, together with modifications in bird and vector ecology, are leading to the arise of emerging pathogens in new geographical locations, and these zoonotic New World arboviruses are gaining concern. Novel vaccine development does show a promising future for prevention of these infections in both horses and humans.Instituto de VirologíaFil: Carossino, Mariano. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virologia; Argentina. Universidad del Salvador. Escuela de Veterinaria; ArgentinaFil: Thiry, Etienne. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; BélgicaFil: Grandière, Ana de la. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; BélgicaFil: Barrandeguy, Maria Edith. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Universidad del Salvador. Escuela de Veterinaria; ArgentinaElsevier2019-01-25T17:12:50Z2019-01-25T17:12:50Z2014-01-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://www.sciencedirect.com/science/article/pii/S0264410X13016332http://hdl.handle.net/20.500.12123/43360264-410Xhttps://doi.org/10.1016/j.vaccine.2013.11.071Vaccine 32 (3) : 311-319 (January 2014)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/restrictedAccess2025-10-23T11:16:49Zoai:localhost:20.500.12123/4336instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-23 11:16:49.319INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Novel vaccination approaches against equine alphavirus encephalitides
title Novel vaccination approaches against equine alphavirus encephalitides
spellingShingle Novel vaccination approaches against equine alphavirus encephalitides
Carossino, Mariano
Caballos
Enfermedades de los Animales
Alphavirus
Virus de la Encéfalo Mielitis Equina
Vacunación
Horses
Animal Diseases
Equine Encephalomyelitis Virus
Vaccination
title_short Novel vaccination approaches against equine alphavirus encephalitides
title_full Novel vaccination approaches against equine alphavirus encephalitides
title_fullStr Novel vaccination approaches against equine alphavirus encephalitides
title_full_unstemmed Novel vaccination approaches against equine alphavirus encephalitides
title_sort Novel vaccination approaches against equine alphavirus encephalitides
dc.creator.none.fl_str_mv Carossino, Mariano
Thiry, Etienne
Grandière, Ana de la
Barrandeguy, Maria Edith
author Carossino, Mariano
author_facet Carossino, Mariano
Thiry, Etienne
Grandière, Ana de la
Barrandeguy, Maria Edith
author_role author
author2 Thiry, Etienne
Grandière, Ana de la
Barrandeguy, Maria Edith
author2_role author
author
author
dc.subject.none.fl_str_mv Caballos
Enfermedades de los Animales
Alphavirus
Virus de la Encéfalo Mielitis Equina
Vacunación
Horses
Animal Diseases
Equine Encephalomyelitis Virus
Vaccination
topic Caballos
Enfermedades de los Animales
Alphavirus
Virus de la Encéfalo Mielitis Equina
Vacunación
Horses
Animal Diseases
Equine Encephalomyelitis Virus
Vaccination
dc.description.none.fl_txt_mv The current production of inactivated vaccines for the prevention of equine alphavirus encephalitides caused by Eastern, Western and Venezuelan Equine Encephalitis viruses (EEEV, WEEV, VEEV) involves the manipulation of large quantities of infectious viral particles under biosafety level 3 containment laboratories with the potential risk of transmission to the operators. Moreover, these vaccines are not capable of inducing a long-lasting immunity. Modified live vaccines, which were also attempted, maintain residual virulence and neurotropism, causing disease in both horses and humans. Therefore, the production of an efficacious second generation vaccine which could be used in the prevention of alphavirus infection without the need to manipulate infectious viral particles under high biocontainment conditions could be of great benefit for the worldwide horse industry. Furthermore, equine alphaviruses are considered as biological threat agents. Subunit, chimeric, gene-deleted live mutants, DNA and adenovirus-vectored alphavirus vaccines have been evaluated; such approaches are reviewed in this work. Climate changes, together with modifications in bird and vector ecology, are leading to the arise of emerging pathogens in new geographical locations, and these zoonotic New World arboviruses are gaining concern. Novel vaccine development does show a promising future for prevention of these infections in both horses and humans.
Instituto de Virología
Fil: Carossino, Mariano. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virologia; Argentina. Universidad del Salvador. Escuela de Veterinaria; Argentina
Fil: Thiry, Etienne. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; Bélgica
Fil: Grandière, Ana de la. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; Bélgica
Fil: Barrandeguy, Maria Edith. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Universidad del Salvador. Escuela de Veterinaria; Argentina
description The current production of inactivated vaccines for the prevention of equine alphavirus encephalitides caused by Eastern, Western and Venezuelan Equine Encephalitis viruses (EEEV, WEEV, VEEV) involves the manipulation of large quantities of infectious viral particles under biosafety level 3 containment laboratories with the potential risk of transmission to the operators. Moreover, these vaccines are not capable of inducing a long-lasting immunity. Modified live vaccines, which were also attempted, maintain residual virulence and neurotropism, causing disease in both horses and humans. Therefore, the production of an efficacious second generation vaccine which could be used in the prevention of alphavirus infection without the need to manipulate infectious viral particles under high biocontainment conditions could be of great benefit for the worldwide horse industry. Furthermore, equine alphaviruses are considered as biological threat agents. Subunit, chimeric, gene-deleted live mutants, DNA and adenovirus-vectored alphavirus vaccines have been evaluated; such approaches are reviewed in this work. Climate changes, together with modifications in bird and vector ecology, are leading to the arise of emerging pathogens in new geographical locations, and these zoonotic New World arboviruses are gaining concern. Novel vaccine development does show a promising future for prevention of these infections in both horses and humans.
publishDate 2014
dc.date.none.fl_str_mv 2014-01-09
2019-01-25T17:12:50Z
2019-01-25T17:12:50Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0264410X13016332
http://hdl.handle.net/20.500.12123/4336
0264-410X
https://doi.org/10.1016/j.vaccine.2013.11.071
url https://www.sciencedirect.com/science/article/pii/S0264410X13016332
http://hdl.handle.net/20.500.12123/4336
https://doi.org/10.1016/j.vaccine.2013.11.071
identifier_str_mv 0264-410X
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
eu_rights_str_mv restrictedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Vaccine 32 (3) : 311-319 (January 2014)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1846787517577166848
score 12.982451

Publicaciones similares